Everything below concerns deamidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-17. Numbers and descriptions here follow the published literature rather than marketing material.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
=== Magnetic === In 2015 researchers announced a graphene-based magnetic sensor 100 times more sensitive than an equivalent device based on silicon (7,000 volts per amp-tesla). The sensor substrate was hexagonal boron nitride. The sensors were based on the Hall effect, in which a magnetic field induces a Lorentz force on moving electric charge carriers, leading to deflection and a measurable Hall voltage. In the worst case graphene roughly matched a best case silicon design. In the best case graphene required lower source current and power requirements.
== Discovery == In 1887, Élie Metchnikoff observed that leukocytes isolated from the blood of various animals were attracted towards certain bacteria. This attraction was soon proposed to be due to soluble elements released by the bacteria (see Harris for a review of this area up to 1953). Peter Ward, Elmer Becker, Henry Showell, and colleagues showed that these elements were made by a variety of growing gram positive bacteria and gram negative bacteria and were of low molecular weight, i.e. below 3600 Dalton (unit)s. Further studies by Schiffmann and colleges found that cultures of growing Escherichia coli released oligopeptides of between 150 and 1500 daltons that appeared to have a free carboxylic acid group but not a free amine group. Given these clues and knowledge that bacteria transcribe proteins starting with N-formylmethionine whereas eukaryotic cells mostly initiate protein synthesis with non-formylated methionine, Schiffmann, Corcoran, and Wahl theorized and then showed that N-formyl-methionine and a series N-formyl-methionyl dipeptides and tripeptides stimulated the chemotaxis of neutrophils isolated from rabbit peritoneal exudates as well as of macrophages isolated from guinea pig peritoneal exudates. In further studies of various N-formylated oligopeptides, fMLF proved the most potent in stimulating rabbit neutrophil chemotaxis.
The letter stated, "Our organizations deplore the use of chlorine in this manner. The indiscriminate attacks, possibly carried out by a member state of the Chemical Weapons Convention (CWC), are of concern to chemical scientists and engineers around the globe and we stand ready to support your mission of implementing the CWC." According to the CWC, "the use, stockpiling, distribution, development or storage of any chemical weapons is forbidden by any of the 192 state party signatories."
== Analogue controls == Several jurisdictions have implemented analogue law controls of fentanyl analogues in an attempt to pre-emptively ban novel derivatives before they appear on the market. One representative example is the New Zealand provisions enacted in 1988 in response to the first wave of fentanyl derivatives. This bans a set of structures as follows; "Fentanyl analogues, in which the N-[1-(2-phenethyl)-4-piperidyl]aniline nucleus has additional radicals, either alone or in combination, attached as follows: (a) an acetyl, propionyl, butenoyl or butanoyl radical, attached to the aniline nitrogen atom: (b) 1 or more alkyl radicals, with up to 10 carbon atoms in total, attached to the ethyl moiety: (c) any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals, attached to each of the benzene rings." A more recent and somewhat broader example was introduced into US Federal legislation in 2018, covering the following structures; "...fentanyl-related substances includes any substance not otherwise controlled in any schedule...that is structurally related to fentanyl by one or more of the following modifications:
Sources: en.wikipedia.org
The European Central Bank's 'primary objective... shall be to maintain price stability. Without prejudice to that objective, it shall support the general economic policies in the Union', such as 'balanced economic growth and price stability, a highly competitive social market economy, aiming at full employment and social progress, and a high level of protection and improvement of the quality of the environment.' There are three main powers to achieve these goals. First, the ECB can require other banks to hold reserves proportionate to their type of lending. Second, it may lend money to other banks, or conduct 'credit operations'. Third it may 'operate in the financial markets by buying and selling' securities. For example, in Gauweiler v Deutscher Bundestag a German politician claimed that the ECB's purchase of Greek government debt on secondary markets violated TFEU article 123, which prohibits directly lending money to member state governments. The Court of Justice rejected that the ECB had engaged in 'economic policy' (i.e. fiscal transfers) rather than monetary policy decisions, which it was allowed to do. So far the ECB has failed to use these powers to eliminate investment in fossil fuels, despite the inflation that gas, oil and coal cause given their price volality in international markets. Beyond the central bank, the Credit Institutions Directive 2013 requires authorisation and prudence provisions in other banks in all EU member states.
In periodontology, gingival grafting, also called gum grafting or periodontal plastic surgery, is a generic term for the performance of any of a number of surgical procedures in which the gingiva (gum tissue) is grafted. The aim may be to cover exposed root surfaces or merely to augment the band of keratinized tissue.
== Treatment == Treatment for myositis depends on the underlying cause. For myositis, which is caused by a viral infection, no treatment is typically needed. For myositis caused by a bacterial infection, antibiotics can be used. For myositis caused by a medication, it is important to stop using that medication. There are a variety of treatment options available if myositis is caused by an autoimmune disease. Glucocorticoids are often the first choice for treatment. This drug works to weaken the immune system so that it is not able to attack the muscles. It is a type of steroid and can cause a wide array of side effects, such as mood changes, increased hunger, trouble sleeping, etc. Another treatment option is a steroid-sparing immunosuppressive agent. This also works to weaken the immune system but does not cause the side effects that steroids do. Another treatment option is a class of drugs called biologics. Also, intravenous immunoglobulins (IVIg) have been shown to be effective in the treatment of myositis caused by an autoimmune disease.
Sources: en.wikipedia.org
However, those whose symptoms had remitted were significantly more likely to have good relationships with a romantic partner and at least one parent, good performance at work and school, a sustained work and school history, and good psychosocial functioning overall. Estimates of the lifetime risk of death by suicide among individuals with BPD range between 3% and 10%, varying with the method of investigation. In a study examining completed suicides among individuals aged 18 to 35, 30% of the suicides were attributed to people with BPD, with a majority being men, and almost none receiving treatment. Similar findings were reported in another study. Among men diagnosed with BPD, there is also evidence of a higher suicide rate: "men are more than twice as likely as women—18 percent versus 8 percent"—to die by suicide. There is evidence that a significant proportion of males who die by suicide may have undiagnosed BPD. About half of all individuals who commit suicide are diagnosed with a personality disorder, with BPD being the most common association.
Cottage cheese was widely promoted in America during the First World War, along with other dairy products, to save meat for infantry rations. This promotion was shown in many war posters, including one which claimed that one pound of cottage cheese contains more protein than a pound of lamb, pork, beef, or chicken. After the war, cottage cheese quickly became more commonly consumed. Thirty million pounds (14,000 t) of cottage cheese were produced in 1919 (out of 418,000,000 pounds (190,000 t) of cheese in general in 1920), and by 1928, 87,000,000 pounds (39,000 t) were manufactured. Consumption peaked in the United States in the 1970s when dieting became common, and some $1.3 billion of cottage cheese was sold per year. Market reviews for the cottage cheese indicate it may have a resurgence in consumer interest during the 21st century by comparison to Greek yogurt, as both foods provide a high protein and low-sugar dietary choice. In 2026, increased consumption of cottage cheese in the United States as a high-protein food source induced cheese factories in Wisconsin and other states to modify equipment to meet the elevated demand.
When simple salts dissolve, they dissociate into individual ions, which are solvated and dispersed throughout the resulting solution. Salts do not exist in solution. In contrast, molecular compounds, which includes most organic compounds, remain intact in solution. The solubility of salts is highest in polar solvents (such as water) or ionic liquids, but tends to be low in nonpolar solvents (such as petrol/gasoline). This contrast is principally because the resulting ion–dipole interactions are significantly stronger than ion-induced dipole interactions, so the heat of solution is higher. When the oppositely charged ions in the solid ionic lattice are surrounded by the opposite pole of a polar molecule, the solid ions are pulled out of the lattice and into the liquid. If the solvation energy exceeds the lattice energy, the negative net enthalpy change of solution provides a thermodynamic drive to remove ions from their positions in the crystal and dissolve in the liquid. The enthalpy change of solution is usually positive for most solid solutes like salts, which means that their solubility increases when the temperature increases. There are some unusual salts such as calcium hydroxide, where this enthalpy change is negative and the solubility decreases with temperature. The lattice energy, the cohesive forces between these ions within a solid, determines the solubility. The solubility is dependent on how well each ion interacts with the solvent, so certain patterns become apparent. For example, salts of sodium, potassium and ammonium are usually soluble in water.
== Mode of action == For its immunotoxic properties, a low concentration of MCD peptide can cause mast cell degranulation by releasing histamine; at higher concentrations it displays anti-inflammatory activities. Through its effect on ionic channels, MCD peptide can induce long term potentiation (LTP) in CA1 region of hippocampus. It binds and inactivates voltage-dependent K+ channels, including fast-inactivating (A-type) and slow-inactivating (delayed rectifier) K+ channels. The binding site of the MCD peptide on the K+ ion channel protein complex is a multimeric protein, consisting of polypeptide chains of molecular weight between 76,000 and 80,000 and 38,000 daltons. By blocking potassium channels, the MCD peptide can increase the duration of action potentials and increase neuronal excitability.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.